Andrew R. de Guttadauro
Presidente presso Oncolytics Biotech (U.S.), Inc.
Patrimonio netto: 11 037 $ in data 31/05/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Kirk Look | M | - |
Oncolytics Biotech (U.S.), Inc.
 Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ronald B. Moss | M | 64 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 anni |
| Mary Ann Dillahunty | F | - |
Oncolytics Biotech (U.S.), Inc.
Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
| Richard Kenney | M | 66 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 4 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Andrew R. de Guttadauro
- Contatti personali
